Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleAmylin's $7 billion GLP-1 deal.AuthorsOrelli, BrianAbstractThe article informs that Bristol-Myers Squibb Co. (BMS) has announced to sell half of Amylin Pharmaceuticals Inc.'s assets to AstraZeneca PLC.SubjectsBRISTOL-Myers Squibb Co.; AMYLIN Pharmaceuticals Inc.; ASTRAZENECA PLCPublicationNature Biotechnology, 2012, Vol 30, Issue 8, p730ISSN1087-0156Publication typeArticleDOI10.1038/nbt0812-730a